Sandwich, UK — 10 June 2026: Discovery Park, Kent’s science and innovation hub, has launched the seventh edition of its Discovery Spark accelerator programme, welcoming 12 startups to its campus in Sandwich.
The seventh cohort is themed around innovations in health, with startups selected based on the need for their innovation, the uniqueness of their solution, and the strength of their team. Throughout June, the selected founders will be attending specialist-led sessions in both Kent and London, focused on investor readiness, covering essential business topics from tax and finance,…
· Next-generation small molecule microtubule targeting agent, PMC-001, progressing towards Phase 1
· Comprehensive preclinical data package demonstrates differentiating oral activity and CNS penetration, unlocking treatment of primary and secondary brain cancers
· Dr Gabriel Fox appointed as Chief Medical Officer to lead clinical development
Cambridge, UK: PhoreMost Limited (“PhoreMost”), a biotech company focused on turning scientific breakthroughs into life-changing…
Grant awarded through the Parkinson's Disease Therapeutics Pipeline Program to support advancement of Harness' new programme targeting GCase and LIMP2 for Parkinson's disease
Two-year programme expands Harness' neurodegenerative disease pipeline, leveraging proprietary MISBA® platform
Cambridge, UK, 9 June 2026: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces it has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (…
Amsbio announce the availability of fresh whole blood products from diverse, healthy donors now with overnight delivery in the US, Europe and the UK in conjunction with sister company - Research Donors. All these premium human blood biospecimens undergo rigorous serology screening and rapid processing to ensure maximum viability.
Supplied with donor diversity data including age, sex, blood type and other characteristics, all fresh blood products come fully consented with compliance documentation for genetic analysis, biomarker discovery and commercial research.
Sourcing blood products for…
Deep Science Ventures (DSV), a UK-based deeptech venture creator, and Medicines Discovery Catapult (MDC), a life sciences service dedicated to turning drug discovery into commercial breakthroughs, today announced a strategic collaboration to address challenges in delivering medicines into the brain.
One of medicine’s greatest challenges is ensuring that treatments reach the precise area of the body where they are needed. While recent scientific breakthroughs have identified numerous targets for neurological conditions, the difficulty of effectively transporting these treatments across the…
Appointments bring deep commercial, scaling, life science, healthcare, and diagnostics expertise to accelerate growth and delivery of clinical impactOxford, UK – 3 June 2026 – PrecisionLife, a leader in AI-driven precision medicine for chronic diseases, today announced the appointments of Dr Pradip Banerjee, PhD, MBA, as an Independent Non-Executive Director and Dr Kam Pooni, PhD, as Chief Product Officer. These strategic hires further strengthen the company’s leadership as it scales from a pioneering technology innovator to a commercial organization delivering real-world healthcare impact.Dr…
LONDON, UK and VALENCIA, Spain – June 2, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Quibim and is pleased to announce the placement of Itta MacNevin as Chief Business Officer (CBO). Quibim is a global pioneer in imaging biomarkers for precision medicine. The Company’s AI-powered, imaging-based solutions enable pharmaceutical companies to predict which patients will respond to a drug, identify suitable candidates for clinical trials, stratify patients by risk, and…
• Drug Discovery 2026 returns to ExCeL London from 14–15 October to celebrate 20 years of collaboration and inclusion
• Keynote programme includes presentation from Dr Sam Barrell CBE and panel discussion with Dr Anne Phelan, Dr Jason Mellad, Prof Sir Mene Pangalos and Prof Raghib Ali OBE
• Key topics include next-generation biophysics, microbes to medicines, multiomics, AI in compound discovery and experimental design, and bioconjugation approaches in oncology
Cambridge, UK, 01 June 2026: ELRIG, a not-for-profit, volunteer-led organisation dedicated to the global drug discovery community,…
Phase I study of an AI-designed oral formulation sets a new standard in drug developmentNOTTINGHAM, UK – 28 MAY 2026: Quotient Sciences today announces the successful initiation of a clinical study evaluating a novel drug product developed using artificial intelligence (AI) - a landmark achievement highlighting the growing potential of AI to guide formulation design and accelerate drug development. The pioneering Phase I clinical study was initiated at Quotient Sciences’ UK facility following approval from the Medicines and Healthcare products Regulatory Agency (MHRA). The study will…
1 June 2026
Researching the pros and cons of Annual Award Dinners and Company Showcase Pitching at conferences, respecting that the role of a not-for-profit membership organisation is to maximise support whilst mitigating any incurred overhead on its members, One Nucleus has transformed their approach to two of their flagship annual events. The Annual Awards will now form a key element within Genesis on Thursday 10 December in London.
There are three distinct advantages for our network:
Enabling greater connectivity and visibility to complement the profile and branding advantages of award-…